{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:12:37Z","timestamp":1792429957721,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ygyno.2020.12.025","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T07:42:21Z","timestamp":1609400541000},"page":"688-695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["A phase Ib\/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer"],"prefix":"10.1016","volume":"160","author":[{"given":"L.R.","family":"Duska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.N.","family":"Krasner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Hays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.C.","family":"Modesitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.H.","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Purdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.C.","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.T.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"Supko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2020.12.025_bb0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ygyno.2020.12.025_bb0010","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2020.12.025_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"13","key":"10.1016\/j.ygyno.2020.12.025_bb0020","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ygyno.2020.12.025_bb0025","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2165\/11591720-000000000-00000","article-title":"Management strategies for recurrent platinum-resistant ovarian cancer","volume":"71","author":"Naumann","year":"2011","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ygyno.2020.12.025_bb0030","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.ygyno.2020.12.025_bb0035","doi-asserted-by":"crossref","first-page":"42408","DOI":"10.18632\/oncotarget.9878","article-title":"Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis","volume":"7","author":"Lin","year":"2016","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.ygyno.2020.12.025_bb0040","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1073\/pnas.1603018113","article-title":"CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing","volume":"113","author":"Clark","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.ygyno.2020.12.025_bb0045","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s10637-012-9921-8","article-title":"First-in-human phase 1\/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies","volume":"31","author":"Weiss","year":"2013","journal-title":"Invest New Drugs"},{"issue":"5s","key":"10.1016\/j.ygyno.2020.12.025_bb0050","article-title":"Phase II clinical trial evaluating CRLX101 in recurrent ovarian, tubal and peritoneal cancer","volume":"32","author":"Krasner","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ygyno.2020.12.025_bb0055","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrclinonc.2010.120","article-title":"Weekly paclitaxel in the treatment of recurrent ovarian cancer","volume":"7","author":"Baird","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2020.12.025_bb0060","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Gynecologic Oncology","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.ygyno.2020.12.025_bb0065","first-page":"1843","article-title":"The microtubule-affecting drug paclitaxel has antiangiogenic activity","volume":"2","author":"Belotti","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ygyno.2020.12.025_bb0070","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1158\/1078-0432.CCR-08-2710","article-title":"Antivascular actions of microtubule-binding drugs","volume":"15","author":"Schwartz","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ygyno.2020.12.025_bb0075","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ijc.20595","article-title":"Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition","volume":"113","author":"Merchan","year":"2005","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2020.12.025_bb0080","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2009.27.8911","article-title":"Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"29","author":"Sehouli","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2020.12.025_bb0085","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00280-006-0383-6","article-title":"Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer","volume":"60","author":"Stathopoulos","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.ygyno.2020.12.025_bb0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00280-004-0814-1","article-title":"Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I\/II study","volume":"54","author":"Stathopoulos","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"issue":"16","key":"10.1016\/j.ygyno.2020.12.025_bb0095","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1016\/j.ejca.2010.06.124","article-title":"Paclitaxel\/carboplatin versus topotecan\/paclitaxel\/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study","volume":"46","author":"Bolis","year":"2010","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2020.12.025_bb0100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1006\/gyno.2002.6811","article-title":"A phase I study of weekly topotecan and Paclitaxel in previously treated epithelial ovarian carcinoma patients","volume":"87","author":"Homesley","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ygyno.2020.12.025_bb0105","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/annonc\/mdw188","article-title":"Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial","volume":"27","author":"Keefe","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ygyno.2020.12.025_bb0110","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s00280-005-0091-7","article-title":"Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice","volume":"57","author":"Schluep","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ygyno.2020.12.025_bb0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2174\/157340711795163866","article-title":"CRLX101 (formerly IT-101)-A Novel Nanopharmaceutical of Camptothecin in Clinical Development","volume":"7","author":"Young","year":"2011","journal-title":"Curr Bioact Compd"},{"issue":"1","key":"10.1016\/j.ygyno.2020.12.025_bb0120","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.nano.2013.07.005","article-title":"Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents","volume":"10","author":"Schell","year":"2014","journal-title":"Nanomedicine"},{"issue":"9","key":"10.1016\/j.ygyno.2020.12.025_bb0125","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1517\/17425255.2015.1057496","article-title":"Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents","volume":"11","author":"Lucas","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.ygyno.2020.12.025_bb0130","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.clinthera.2015.12.009","article-title":"Pharmacokinetics of Weekly Paclitaxel and Feasibility of Dexamethasone Taper in Japanese Patients with Advanced Non-small Cell Lung Cancer","volume":"38","author":"Nokihara","year":"2016","journal-title":"Clin Ther"},{"issue":"3 Suppl 6","key":"10.1016\/j.ygyno.2020.12.025_bb0135","first-page":"16","article-title":"Paclitaxel pharmacokinetics and pharmacodynamics","volume":"22","author":"Kearns","year":"1995","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2020.12.025_bb0140","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.1995.13.1.180","article-title":"Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic\/pharmacodynamic relationships in humans","volume":"13","author":"Gianni","year":"1995","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2020.12.025_bb0145","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.1999.17.2.676","article-title":"Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer","volume":"17","author":"Belani","year":"1999","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820342281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820342281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:55:26Z","timestamp":1758772526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820342281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0090825820342281"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.12.025","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase Ib\/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}